A case of 5-fluorouracil-induced hyperammmonia after chemotherapy for metastatic colon cancer

Journal of Japanese Society of Gastroenterology

Volumn 106, Issue 12, 2009, Pages 1744-1750

  Nakamura, Masamoto ^a   Kobashikawa, Kasen ^a   Tamura, Jiro ^a   Takaki, Ryo ^a   Ohshiro, Masaru ^a   Matayoshi, Ryoji ^a,b   Hirata, Tetsuo ^c   Kinjyo, Fukunori ^c   Fujita, Jiro ^c  

^a Okinawa Red Cross Hospital   (Japan)

^b Matayoshi Clinic   (Japan)

^c UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; AMMONIA BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COLON CANCER; CONSERVATIVE TREATMENT; FEMALE; HUMAN; HYPERAMMONEMIA; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; HYPERAMMONEMIA; LEUCOVORIN; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 75249103979     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Grothey A, Sargent D, Goldberg RM,etal:Survival of patients with advanced colorectal cancer improves with the avaUability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 ; 1209-1214 : 2004
2. Petrelli N, Douglass HO Jr, Herrera L, et al : The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma : a prospective randomized phase III trial Gastrointestinal Tumor Study Group. J CUn Oncol 7 ; 1419-1426:1989
3. Poon MA, O'Connell MJ, Wieand HS,etal:Biochemical modulation of fluorouracil with leucovorin : confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9 ; 1967-1972:1991
4. de Gramont A, Bosset JF, Müan C, et al : Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol 15 ; 808-815:1997
5. Könne CH, Wils J, Lorenz M, et al : Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer : European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 15 ; 3721-3728:2003
6. de Gramont A, Figer A, Seymour M, et al : Leucovorin and fluorouracU with or without oxaliplatin as first-Une treatment in advanced colorectal cancer. J Clin Oncol 18 ; 2938-2947:2000
7. Tornigand C, André T, Achille E, et al : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study. J Clin Oncol 22 ; 229-237:2004
8. Saltz LB, Clarkes S. Diaz-Rubio E, et al : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study. J Clin Oncol 26 ; 2013-2019:2008
9. Grothey A, Sugrue MM, Purdie DM, et al : Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer : results from a large observational cohort study (BRiTE). J Clin Oncol 26 ; 5326-5334:2008
10. Van Cutsem E, Köhne CH, Hitre E, et al : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 ; 1408-1417:2009
11. Cheung WY, Fralick RA, Cheng S : The confused cancer patient:a case of 5-fluorouracil-induced encephalopathy. Curr Oncol 15 ; 234-236:2008
12. Kim YA, Chung HC, Choi HJ, et al : Intermediated dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 36 ; 55-59:2006
13. Lin YC. Chen JS, Wang CH, et al : Weekly highdose 5-fluorouracil (5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer. Jpn J Clin Oncol 31 ; 605-609:2001
14. Japanese source
15. Kikuta S, Asakage T, Nakao K, et al : The aggravating factors of hyperammonemia related to 5-fluorouracil infusion-a report of two cases. Auris Nasus Larynx 35 ; 295-299:2008
16. Liaw CC, Wang HM, Wang CH, et al : Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10 ; 275-281 : 1999
17. Liaw CC, Liaw SJ, Wang CH, et al : Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouraciL Anticancer Drugs 4 ; 311-315:1993
18. Pinedo HM, Peters GJ : Fluorouracil : biochemistry and pharmacology. J Clin Oncol 6:1653-1664 : 1988
19. Clay AS, Hainline BE : Hyperammonemia in the ICU. Chest 132 ; 1368-1378:2007
20. Olde Damink SW, Jalan R, Deutz NE,etal:The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 37 ; 1277-1285:2003
21. Olde Damink SW, Dejong CH, Deutz NE,etal: Kidney plays a major role in ammonia homeostasis after portasystemic shunting in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol 291 ;G189-G194:2006
22. Vince A, Dawson AM, Park N, et al : Ammonia production by intestinal bacteria Gut 14 ; 171-177:1973
23. Koenig H, Patel A : Biochemical basis for fluorouracU neurotoxicity.The role of Rrebs cycle inhibition by fluoroacetate. Arch Neurol 23 ; 155-160 : 1970
24. Ray JD, Hilton-Jones D, Hyman N,etal:Valproate toxicity and ornithine carbamoyltransferase deficiency. Lancet 2 ; 1283-1284:1986
25. Japanese source